Partners Marc J. Ross and James M. Turner Represent Tonix Pharmaceuticals in $10 Million Public Offering of Common Stock
Press Release – New York, NY – June 23, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a developer of next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder, in an underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at a purchase price of $2.00 per share. Tonix raised $10 million in gross proceeds. Roth Capital Partners and National Securities Corporation, a wholly-owned subsidiary of National Holdings, Inc. (NASDAQ:NHLD), acted as joint book-running managers for the offering.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Marc J. Ross and James M. Turner and associate Nazia Khan.
- Sichenzia Ross Ference Carmel LLP 代表 Craft Capital Management 和 D. Boral Capital 参与 Aduro Clean Technologies 的 400 万美元公开发行 - November 8, 2024
- Sichenzia Ross Ference Carmel LLP 代表 Safe & Green Holdings Corp. 进行 240 万美元的认股权证诱导 - November 7, 2024
- Sichenzia Ross Ference Carmel LLP 代表 Thumzup Media Corporation 进行 712.5 万美元的承销公开发行 - October 31, 2024